Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from CLSA Premium Ltd. ( (HK:6877) ) is now available.
The company warned of a roughly HK$7.1 million net loss for 2025 versus a HK$11.3 million profit in 2024 after B2C expansion, higher operating and professional costs, and a 71% slide in other income eroded profitability; management expects improved discipline, product mix upgrades, and streamlined logistics to gradually restore financial performance as one-off expenses fade.
The most recent analyst rating on (HK:6877) stock is a Hold with a HK$0.15 price target. To see the full list of analyst forecasts on CLSA Premium Ltd. stock, see the HK:6877 Stock Forecast page.
More about CLSA Premium Ltd.
Top Eminent Healthcare Group Limited operates in Hong Kong’s healthcare sector, focusing on business-to-consumer services that rely on digital marketing, strategic partnerships, and a refined product mix to reach retail clients.
Average Trading Volume: 641,929
Technical Sentiment Signal: Sell
Current Market Cap: HK$266.4M
See more insights into 6877 stock on TipRanks’ Stock Analysis page.